MedImmune chief, R&D head leave posts

MedImmune chief executive David Mott and the head of research and development, James Young, have resigned, just a year after AstraZeneca PLC's acquisition of the biotech firm. The unexpected departure of Mott, which takes effect at the end of July, and Young, who left his post earlier this month, deals another blow to AstraZeneca and reflects the challenges drugmakers face in keeping prime biotech talent on staff.

View Full Article in:

Wall Street Journal (tiered subscription model), The · Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC